# BCL2L10

## Overview
BCL2L10 is a gene that encodes the BCL2 like 10 protein, a member of the BCL-2 family known for its role in regulating apoptosis. The BCL2 like 10 protein is characterized by its anti-apoptotic function, primarily through maintaining mitochondrial integrity and inhibiting pro-apoptotic proteins. It is predominantly localized in the cytoplasm and mitochondria, where it plays a crucial role in cell survival, particularly during early embryonic development and oocyte maturation (Guérin2013Subcellular; Boumela2011Involvement). The protein's structure includes conserved BH1, BH2, and BH4 domains, but it lacks the BH3 domain, which is typical in other BCL-2 family proteins (Zhang2001Bcl2L10). BCL2L10's interactions with other proteins, such as Ubiquilin1 and BECN1, further modulate its function and localization, influencing apoptosis and autophagy pathways (He2019BCL2L10BECN1; Beverly2012Ubiquitination). The gene's clinical significance is underscored by its involvement in various cancers, including acute myeloid leukemia and hepatocellular carcinoma, where it may serve as a biomarker for treatment resistance and disease progression (Fabiani2010Analysis; He2019BCL2L10BECN1).

## Structure
The BCL2L10 protein is a member of the BCL-2 family, characterized by its anti-apoptotic function. Its primary structure includes conserved BH1, BH2, and BH4 domains, but it lacks the BH3 domain, which is typical in other BCL-2 family proteins (Zhang2001Bcl2L10; Bhargavi2010Homology). The secondary structure of BCL2L10 is predicted to include eight α-helices, similar to other BCL-2 family members like Bcl-xL and Bax (Zhang2001Bcl2L10). The protein also features a unique long amino acid stretch, the LAAS, between the α5 and α6 helices, which is involved in calcium binding and is crucial for its anti-apoptotic function (Guillemin2011Characterization).

The tertiary structure of BCL2L10 involves a central hydrophobic region surrounded by amphipathic helices, forming a hydrophobic groove that facilitates interactions with other proteins (Bhargavi2010Homology). The quaternary structure may involve dimerization with other BCL-2 family proteins, although specific details are not provided in the context (Bhargavi2010Homology).

Post-translational modifications include potential phosphorylation sites, such as a dithreonine motif in the SAAS region, which may influence protein conformation and function (Guillemin2011Characterization). The presence of splice variants or isoforms is not detailed in the provided context.

## Function
BCL2L10, a member of the BCL-2 protein family, plays a crucial role in regulating apoptosis by maintaining mitochondrial integrity and influencing cell survival. In healthy human cells, BCL2L10 is predominantly localized in the cytoplasm and associated with mitochondria, where it functions to prevent apoptosis by inhibiting pro-apoptotic proteins (Guérin2013Subcellular). This mitochondrial localization is consistent across various developmental stages and is associated with healthy embryos, suggesting its role in promoting cell survival during early embryonic development (Guérin2013Subcellular).

BCL2L10 is highly expressed in oocytes and early embryos, indicating its importance in the oocyte-to-embryo transition and early embryogenesis. Its expression decreases rapidly after fertilization, suggesting a role limited to the pre-embryonic genome activation phase (Boumela2011Involvement). The protein's anti-apoptotic function is crucial for cell survival by preventing programmed cell death, and its stability and function are regulated by interactions with other proteins, such as ubiquilin1, which influences its ubiquitination and subcellular localization (Beverly2012Ubiquitination).

In summary, BCL2L10 is involved in maintaining cellular homeostasis by regulating apoptosis, particularly in the context of early embryonic development and oocyte maturation. Its activity is primarily associated with mitochondrial integrity, highlighting its role in cell survival and development.

## Clinical Significance
Alterations in the BCL2L10 gene have been implicated in various cancers, particularly in the context of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The gene's promoter region is frequently hypermethylated in these diseases, which is associated with its upregulation following treatment with demethylating agents like decitabine. This suggests a potential role in the pathogenesis of AML and MDS, and highlights its clinical significance in diagnosis and treatment, especially concerning demethylating therapies (Fabiani2010Analysis).

In myeloid malignancies, the BCL2L10 Leu21Arg variant has been studied, revealing a lower frequency of the -21Arg allele in patients with de novo MDS compared to controls, suggesting a protective effect against developing de novo MDS. However, no significant differences were observed in de novo AML (Fabiani2013TheBCL2L10Leu21Arg).

BCL2L10 expression is also linked to resistance to azacitidine in MDS and AML patients. Overexpression of BCL2L10 is associated with azacitidine resistance, and its knockdown can restore drug sensitivity, indicating its potential as a predictive biomarker for treatment resistance (Cluzeau2012BCL2L10).

In hepatocellular carcinoma (HCC), BCL2L10 interacts with BECN1 to modulate autophagy, impacting tumor progression and response to therapy (He2019BCL2L10BECN1).

## Interactions
BCL2L10, also known as BCLb, is involved in several protein interactions that influence its role in apoptosis regulation. It specifically interacts with Ubiquilin1 (Ubqln), a multidomain protein that facilitates the degradation of ubiquitinated targets. This interaction is unique to BCL2L10 among the BCL2 family proteins and leads to the ubiquitination and stabilization of BCL2L10, affecting its localization and potentially enhancing its anti-apoptotic function (Beverly2012Ubiquitination).

BCL2L10 also interacts with BECN1 (Beclin 1) in hepatocellular carcinoma cells, where it inhibits autophagy by binding to BECN1. This interaction disrupts the BECN1-PI3KC3 complex, which is crucial for autophagy, and is influenced by nutrient conditions (He2019BCL2L10BECN1).

Additionally, BCL2L10 interacts with HIP1R, a protein that can activate caspase 9 and disrupt mitochondrial membrane potential. This interaction enhances the apoptotic effects of HIP1R, suggesting a role in apoptotic pathways (Kim2009HIP1R).

BCL2L10 also forms interactions with UBQLN4, which stabilizes BCL2L10 and prevents mitochondrial outer membrane permeability, contributing to its anti-apoptotic mechanisms (Liu2021UBQLN4).


## References


[1. (Fabiani2010Analysis) Emiliano Fabiani, Giuseppe Leone, Manuela Giachelia, Francesco D’alo’, Mariangela Greco, Marianna Criscuolo, Francesco Guidi, Sergio Rutella, Stefan Hohaus, and Maria Teresa voso. Analysis of genome-wide methylation and gene expression induced by 5-aza-2′-deoxycytidine identifies bcl2l10 as a frequent methylation target in acute myeloid leukemia. Leukemia &amp; Lymphoma, 51(12):2275–2284, November 2010. URL: http://dx.doi.org/10.3109/10428194.2010.528093, doi:10.3109/10428194.2010.528093. This article has 38 citations.](https://doi.org/10.3109/10428194.2010.528093)

[2. (Guérin2013Subcellular) Jean-François Guérin, Aurélie Cornut-Thibaut, Sandrine Giscard-Destaing, Sandrine Pouvreau, Yannis Guillemin, and Abdel Aouacheria. Subcellular dynamics of the maternal cell death regulator bcl2l10 in human preimplantation embryos. Human Reproduction, 28(3):729–739, January 2013. URL: http://dx.doi.org/10.1093/humrep/des443, doi:10.1093/humrep/des443. This article has 7 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/humrep/des443)

[3. (Zhang2001Bcl2L10) H. Zhang. Bcl2-l-10, a novel anti-apoptotic member of the bcl-2 family, blocks apoptosis in the mitochondria death pathway but not in the death receptor pathway. Human Molecular Genetics, 10(21):2329–2339, October 2001. URL: http://dx.doi.org/10.1093/hmg/10.21.2329, doi:10.1093/hmg/10.21.2329. This article has 54 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/10.21.2329)

[4. (Kim2009HIP1R) Jae-Hong Kim, Seongmin Yoon, Miae Won, Se-Hoon Sim, Jeong-Jae Ko, Seung Han, Kyung-Ah Lee, Kangseok Lee, and Jeehyeon Bae. Hip1r interacts with a member of bcl-2 family, bcl2l10, and induces bak-dependent cell death. Cellular Physiology and Biochemistry, 23(1–3):043–052, 2009. URL: http://dx.doi.org/10.1159/000204088, doi:10.1159/000204088. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.1159/000204088)

[5. (Beverly2012Ubiquitination) Levi J. Beverly, William W. Lockwood, Parag P. Shah, Hediye Erdjument-Bromage, and Harold Varmus. Ubiquitination, localization, and stability of an anti-apoptotic bcl2-like protein, bcl2l10/bclb, are regulated by ubiquilin1. Proceedings of the National Academy of Sciences, January 2012. URL: http://dx.doi.org/10.1073/pnas.1119167109, doi:10.1073/pnas.1119167109. This article has 55 citations.](https://doi.org/10.1073/pnas.1119167109)

[6. (He2019BCL2L10BECN1) Jiafa He, Li Deng, Heping Liu, Taiying Chen, Shengying Chen, Shangzhou Xia, and Yubin Liu. Bcl2l10/becn1 modulates hepatoma cells autophagy by regulating pi3k/akt signaling pathway. Aging, 11(2):350–370, January 2019. URL: http://dx.doi.org/10.18632/aging.101737, doi:10.18632/aging.101737. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.18632/aging.101737)

[7. (Fabiani2013TheBCL2L10Leu21Arg) Emiliano Fabiani, Luana Fianchi, Giulia Falconi, Riccardo Boncompagni, Marianna Criscuolo, Francesco Guidi, Antonella La Brocca, Stefan Hohaus, Giuseppe Leone, and Maria Teresa Voso. Thebcl2l10leu21arg variant and risk of therapy-related myeloid neoplasms andde novomyelodysplastic syndromes. Leukemia &amp; Lymphoma, 55(7):1538–1543, November 2013. URL: http://dx.doi.org/10.3109/10428194.2013.845885, doi:10.3109/10428194.2013.845885. This article has 22 citations.](https://doi.org/10.3109/10428194.2013.845885)

[8. (Liu2021UBQLN4) Fang Liu, RunSang Pan, HongYu Ding, LiLing Gu, Yun Yang, ChuanYin Li, YongJie Xu, Ronggui Hu, Hui Chen, XiangYan Zhang, and YingJie Nie. Ubqln4 is an atm substrate that stabilizes the anti‐apoptotic proteins bcl2a1 and bcl2l10 in mesothelioma. Molecular Oncology, 15(12):3738–3752, August 2021. URL: http://dx.doi.org/10.1002/1878-0261.13058, doi:10.1002/1878-0261.13058. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/1878-0261.13058)

[9. (Boumela2011Involvement) Imene Boumela, Said Assou, Abdel Aouacheria, Delphine Haouzi, Hervé Dechaud, John De Vos, Alan Handyside, and Samir Hamamah. Involvement of bcl2 family members in the regulation of human oocyte and early embryo survival and death: gene expression and beyond. REPRODUCTION, 141(5):549–561, May 2011. URL: http://dx.doi.org/10.1530/rep-10-0504, doi:10.1530/rep-10-0504. This article has 64 citations and is from a peer-reviewed journal.](https://doi.org/10.1530/rep-10-0504)

[10. (Cluzeau2012BCL2L10) Thomas Cluzeau, Guillaume Robert, Nicolas Mounier, Jean Michel Karsenti, Maeva Dufies, Alexandre Puissant, Arnaud Jacquel, Aline Renneville, Claude Preudhomme, Jill-Patrice Cassuto, Sophie Raynaud, Frederic Luciano, and Patrick Auberger. Bcl2l10 is a predictive factor for resistance to azacitidine in mds and aml patients. Oncotarget, 3(4):490–501, April 2012. URL: http://dx.doi.org/10.18632/oncotarget.481, doi:10.18632/oncotarget.481. This article has 71 citations and is from a poor quality or predatory journal.](https://doi.org/10.18632/oncotarget.481)

[11. (Bhargavi2010Homology) K. Bhargavi, P. Kalyan Chaitanya, D. Ramasree, M. Vasavi, D. K. Murthy, and V. Uma. Homology modeling and docking studies of human bcl-2l10 protein. Journal of Biomolecular Structure and Dynamics, 28(3):379–391, December 2010. URL: http://dx.doi.org/10.1080/07391102.2010.10507367, doi:10.1080/07391102.2010.10507367. This article has 37 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/07391102.2010.10507367)

[12. (Guillemin2011Characterization) Y. Guillemin, A. Cornut-Thibaut, G. Gillet, F. Penin, and A. Aouacheria. Characterization of unique signature sequences in the divergent maternal protein bcl2l10. Molecular Biology and Evolution, 28(12):3271–3283, June 2011. URL: http://dx.doi.org/10.1093/molbev/msr152, doi:10.1093/molbev/msr152. This article has 10 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/molbev/msr152)